Clinical pharmacology of novel selective COX-2 inhibitors.

@article{Tacconelli2004ClinicalPO,
  title={Clinical pharmacology of novel selective COX-2 inhibitors.},
  author={Stefania Tacconelli and Marta L. Capone and Paola Patrignani},
  journal={Current pharmaceutical design},
  year={2004},
  volume={10 6},
  pages={
          589-601
        }
}
Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed. They have the potential advantage to spare COX-1 activity, thus reducing gastrointestinal toxicity, even when administered at high doses to improve efficacy. They are characterized by different pharmacodynamic and pharmacokinetics features. The higher biochemical selectivity of valdecoxib than… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS